Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ultragenyx Pharmaceutical Affirms FY2025 Sales Guidance of $640.000M-$670.000M vs $657.157M Est

Author: Benzinga Newsdesk | November 04, 2025 04:11pm

2025 Financial Guidance

Ultragenyx reaffirmed its revenue guidance for 2025. Total revenues are expected to grow approximately 14-20% compared to 2024.

Reaffirm for the full year 2025:

  • Total revenue to be in the range of $640 million to $670 million
  • Crysvita revenue to be in the range of $460 million to $480 million
  • Dojolvi revenue to be in the range of $90 million to $100 million

     

Ultragenyx also reaffirmed its net cash used in operations guidance for 2025, which is expected to modestly increase compared to 2024 and its path to full year GAAP profitability in 2027.

Posted In: RARE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist